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ABSTRACT
Background and aims A previous study of ours
indicated that enhancer of zeste homologue 2 (EZH2)
plays an important role in hepatocellular carcinoma
(HCC) tumorigenesis. The aim of the present study was
to investigate the potential diagnostic utility of EZH2 in
HCC.
Methods Immunohistochemistry was performed to
examine the expression dynamics of EZH2 in two
independent surgical cohorts of HCC and non-malignant
liver tissues to develop a diagnostic yield of EZH2, HSP70
and GPC3 for HCC detection. The diagnostic
performances of EZH2 and a three-marker panel in HCC
were re-evaluated by using an additional biopsy cohort.
Results Immunohistochemistry analysis demonstrated
that the sensitivity and specificity of EZH2 for HCC
detection was 95.8% and 97.8% in the testing cohort.
Similar results were confirmed in the validation cohort.
For diagnosis of well-differentiated HCCs, the sensitivity
and specificity were 68.9% and 91.5% for EZH2, 62.5%
and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and
75.0% and 100% for a three-marker panel. In biopsies,
positive cases for at least one marker increased from
large regenerative nodule and hepatocellular adenoma
(0/12) to focal nodular hyperplasia (2/20), dysplastic
nodule (7/25), well-differentiated HCC (16/18) and
moderately and poorly differentiated HCC (54/54). When
at least two positive markers were considered,
regardless of their identity, the positive cases were
detected in 0/12 large regenerative nodules and
hepatocellular adenomas, 0/20 focal nodular
hyperplasias, 0/25 dysplastic nodules, 11/18 well-
differentiated HCCs, 32/37 moderately differentiated
HCCs and 15/17 poorly differentiated HCCs.
Conclusion Our findings suggest that EZH2 protein, as
examined by immunohistochemistry, may serve as
a promising diagnostic biomarker of HCCs, and the use of
a three-marker panel (EZH2, HSP70 and GPC3) can
improve the rate of detection of HCCs in liver biopsy
tissues.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a major lethal
malignancy. The disease has a high prevalence in
southeast Asia and Africa, and the incidence of
HCC has also been steadily increasing in Europe
and America.1 2 Due to the high prevalence of
hepatitis B virus (HBV) infection in Chinese
populations, HBV-related liver cirrhosis and/or
HCC has become one of the main disease burdens
in China. Unfortunately, the long-term prognosis
of patients with HCC remains unsatisfactory
in spite of recent advances in surgical techniques
and medical management.3 This poor outcome is,
in part, attributable to the fact that HCC is
generally diagnosed at a late clinical stage, when
treatments are of limited effectiveness.4 Although
serum a-fetoprotein (AFP) and ultrasonography are
routinely used in diagnosis at present,
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Significance of this study
What is already known about this subject?
< Needle biopsy is recommended to identify the
features of liver malignancies when small
hepatic nodules are detected. Clinically, it is
difficult to make a histological distinction
between well-differentiated hepatocellular carci-
nomas (WD HCCs) and dysplastic nodules
(DNs), especially in liver biopsy tissues. EZH2
plays a key role in the tumorigenesis of HCC.
Increased expression of EZH2 has been
frequently detected in HCC tissues, and has
been correlated with the aggressiveness and
poor prognosis of HCCs.
What are the new findings?
< The staining intensity of EZH2 by immunohisto-
chemistry in WD HCCs is significantly larger
than that in DNs.
< The evaluation of EZH2 expression enables us not
only to discriminate HCCs and non-neoplastic
liver tissue, but also to distinguish WD HCC from
DNs with a high degree of accuracy.
< The combination of the three markers (EZH2,
HSP70 and GPC3) could greatly improve our
ability to diagnose HCCs with better sensitivity
and optimal specificity.
How might it impact on clinical practice in the
foreseeable future?
< The results reported here suggest that EZH2 can
serve as a promising immunomarker of HCCs in
the diagnostic work-up of the liver lesions, and
that the use of a three-marker panel (EZH2,
HSP70 and GPC3) enables HCCs to be detected
more easily in liver biopsies.
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complementing clinical assessments, they have a relatively low
sensitivity and specificity, and are not able to identify small and
early stage HCCs.5 6 To diagnose small and early stage HCCs
clinically, a biopsy of hepatic nodules is usually recommended as
a check on diagnoses deriving from serological and radiological
tests.4 However, it is difficult to make a histological distinction
between early well-differentiated (WD) HCC and certain benign
hepatocellular lesions, such as dysplastic nodule (DN) in liver
biopsy specimens, even for experienced pathologists; while
immunomarkers commonly used by clinicians, such as AFP,
CD34 and carcinoembryonic antigen (CEA), have significant
diagnostic limitations.7e9 There is therefore an urgent need to
discover and identify new biomarkers that can distinguish
between HCCs and other benign liver lesions in liver needle
biopsy tissues.
Enhancer of zeste homologue 2 (EZH2), the catalytic subunit
of polycomb repressive complex 2 (PRC2), has been identified as
the sole histone methyltransferase that methylates histone H3
lysine 27 (H3K27) and mediates transcriptional silencing.10
EZH2 has been found to contribute to the maintenance of cell
identity, cell cycle regulation and oncogenesis.11 12 A previous
study by our group showed that knockdown of EZH2 expres-
sion in HCC cells was sufficient to significantly reverse tumor-
igenicity in a nude mouse model, and demonstrated the
potential therapeutic value of EZH2 inhibition in HCC.13
Recent studies have reported that increased expression of EZH2
was frequently detected in HCC tissues and it was correlated
with the aggressiveness and/or poor prognosis of HCCs.14e16
However, these results were evaluated from a small cohort of
liver tissue samples, and the criteria for evaluation of EZH2
positive expression were ambiguous. The potential utility of
EZH2 as a diagnostic biomarker of HCC in liver resection and
needle biopsy tissues still remains to be demonstrated.
The aim of the present study was to investigate the potential
diagnostic utility of EZH2 in HCCs. We first analysed the protein
levels of EZH2 in a panel of HCC and hepatic cell lines and tissues
by western blotting. We then performed immunohistochemistry
(IHC) to examine the expression pattern of EZH2 in a large
surgical cohort of HCCs and corresponding non-neoplastic liver
tissues. Two other potential molecules, heat-shock protein 70
(HSP70) and glypican 3 (GPC3), have previously beenproposed for
use in the differential diagnosis of hepatocallular nodules. These
molecules provided a predictive power for the diagnosis of early
HCC,17e20 and have been recently identified as two useful
biomarkers in the diagnosis of HCC.21 22 We therefore further
validated the diagnostic value of EZH2 both alone and in combi-
nation with HSP70 and GPC3 by IHC in another independent
surgical cohort ofHCCs and benign hepatic lesions. Finally, we re-
evaluated the diagnostic performances of EZH2, together with
HSP70 and GPC3, in HCCs by using an additional cohort of liver
needle biopsy samples. We now report for the first time that the
expression of EZH2 protein, as examined by IHC, may serve as
a promising diagnostic biomarker of HCC, and that the use of
EZH2 in combinationwithHSP70 andGPC3 improves the rate of
detection of HCCs in liver needle biopsy tissues.
MATERIALS AND METHODS
Cell line and cell cultures
Six HCC cell lines (Huh7, HepG2, 7402, 7721, Hep3B and Lm3)
and one normal hepatic cell line (Lo2) were maintained in
Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum and 1% penicillinestreptomycin at
378C with 5% CO2, in accordance with a previously described
protocol.13
Cohorts
Formalin-fixed, paraffin-embedded, primary HCCs from 212
patients, who underwent initial surgical resection between
March 2003 and August 2006, were randomly selected from the
archives of the Department of Pathology of the First Affiliated
Hospital, Sun Yat-Sen University (Guangzhou, China). We used
these patients as a testing cohort. This cohort of patients with
HCC included 174 (82%) men and 38 (18%) women, with
a median age of 48 years, and their clinico-pathological charac-
teristics are summarised in table 1. Average follow-up time was
28.79 months (median, 22.5 months; range, 1.0e81.0 months).
In parallel, we assessed another randomly collected, indepen-
dent validation cohort of 163 patients diagnosedwith liver disease
between July 2005 andMay 2008. These patients, whose diseases
encompassed 126 HCCs and 37 DNs, underwent initial surgical
treatment at Sun Yat-Sen University Cancer Center (Guangzhou,
China). The 126 patient with HCC included 95 (75.4%) men and
31 (24.6%) women, with a median age of 49.5 years (table 1).
Average duration of follow-up was 23.69 months (median,
23.5 months; range, 1.0e53.0 months). In this cohort, the 37
cases of DNs included 12 (32.4%) women and 25 (67.6%) men.
The ages of the patients ranged from 19 to 72 years, and themean
age was 42.3 years. Patients with HCCwere selected for both the
testing and validation cohorts only if they had been given
a distinctive pathological diagnosis, were undergoing primary and
curative resection, and had not received preoperative anticancer
treatment. Availability of patients’ resection tissues and follow-
up data were also criteria for selection.
We collected an additional cohort of 129 cases of 18-gauge
needle biopsy specimens with hepatic nodules (<3 cm) from
March 2007 to May 2010 in our institutes and from the
Department of Pathology, Guangdong Provincial People’s
Hospital, (Guangzhou, China). To ensure that the pathological
diagnosis of this cohort was accurate, only cases in which the
patients subsequently underwent surgical resection were
selected. The diagnoses of these biopsy tissues were confirmed as
identical to those of the resultant surgically resected specimens.
Of the 129 cases of liver biopsy, 72 were diagnosed as HCC, 25 as
DN, 20 as focal nodular hyperplasia (FNH), six as hepatocellular
adenoma (HA) and six as large regenerative nodule (LRN).
In this study, all diagnoses were formulated by expert
pathologists (H-LR and Q-LW), according to the criteria for
terminology established by the International Working Party.23
Tumour differentiation was based on the criteria of the World
Health Organization Classification of Tumours (2000). Tumour
stage was defined according to the 2002 American Joint
Committee on Cancer/International Union Against Cancer
tumourenodeemetastasis (TNM) classification system.24 In
addition, for EZH2 western blotting analysis, fresh tissue spec-
imens from 10 patients with HCC who underwent surgical
resection were collected in 2009.
Western blotting analysis
Equal amounts of whole cell and tissue lysates were resolved by
SDSepolyacrylamide gel electrophoresis (PAGE) and electro-
transferred on a polyvinylidene difluoride (PVDF) membrane
(Pall, Port Washington, New York, USA). The tissues were then
incubated with primary mouse monoclonal antibodies against
human EZH2 (1:1000 dilution; BD Transduction Laboratories,
Franklin Lakes, New Jersey, USA). The immunoreactive signals
were detected with enhanced chemiluminescence kit (Amer-
sham Biosciences, Uppsala, Sweden). The procedures followed
were conducted in accordance with the manufacturer ’s
instructions.
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Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) were constructed in accordance with
a previously described method.25 Triplicate 0.6 mm diameter
cylinders (two identical cylinders taken from intra-tumoural
tissue and one cylinder from peritumoural tissue) were punched
from representative areas of an individual donor tissue block,
and re-embedded into a recipient paraffin block in a defined
position, using a tissue arraying instrument (Beecher Instru-
ments, Silver Spring, Maryland, USA).
The TMA blocks were cut into 5-mm sections and processed for
IHC in accordance with a previously described protocol.26 TMA
slides were incubated respectively with anti-EZH2 (1:100 dilution;
BD Transduction Laboratories, Franklin Lakes, New Jersey, USA),
anti-HSP70 (1:200 dilution; Santa Cruz Biotechnology, Santa
Cruz, California, USA) and anti-GPC3 (1:100 dilution; BioMosaics,
Burlington, Vermont, USA), and stored overnight at 48C. Immu-
nostaining was performed using the Envision System with
diaminobenzidine (Dako, Glostrup, Denmark). A negative
control was obtained by replacing the primary antibody with
a normal murine or rabbit IgG. In the case of non-informative
TMA samples (ie, samples with <500 tumour cells per case and
lost samples), IHC staining was performed by using whole tissue
slides.
Evaluation by immunohistochemistry
Immunoreactivity for EZH2, HSP70 and GPC3 proteins was
scored using a semi-quantitative method by evaluating the
number of positive tumour cells over the total number of
tumour cells. Scores were assigned by using 5% increments (0%,
5%, 10%. 100%), as in our previous study.26 Expression for the
markers was assessed by three independent pathologists (M-YC,
H-LR and DX), who were blinded to the clinicopathological
data. Their conclusions agreed in approximately 81% of the
cases, indicating that this scoring method is highly reproducible.
If two or three assessments were consistent with the results
they scored, that value was selected. In cases where completely
different results occurred, the three assessors discussed their
assessments and agreed on the appropriate score to award.
Table 1 Association of enhancer of zeste homolog 2 (EZH2) expression with patients’ clinicopathological features in primary hepatocellular
carcinomas
Variable
EZH2 protein
Validation cohortTesting cohort
All cases
Negative
expression
Positive
expression p Value* All cases
Negative
expression
Positive
expression p Value*
Age (years) 0.104 0.892
#47.9y 105 9 (8.6%) 96 (91.4%) 61 8 (13.1%) 53 (86.9%)
>47.9 107 17 (15.9%) 90 (84.1%) 65 8 (12.3%) 57 (87.7%)
Sex 0.718 0.510
Male 174 22 (12.6%) 152 (87.4%) 109 13 (11.9%) 96 (88.1%)
Female 38 4 (10.5%) 34 (89.5%) 17 3 (17.6%) 14 (82.4%)
Hepatitis history 0.578 0.661
Yes 164 19 (11.6%) 145 (88.4%) 107 13 (12.1%) 94 (87.9%)
No 48 7 (14.6%) 41 (85.4%) 19 3 (15.8%) 16 (84.2%)
a-Fetoprotein (ng/ml) 0.210 0.309
#20 67 11 (16.4%) 56 (83.6%) 56 9 (16.1%) 47 (83.9%)
>20 145 15 (10.3%) 130 (89.7%) 70 7 (10.0%) 63 (90.0%)
Liver cirrhosis 0.608 0.064
Yes 132 15 (11.4%) 117 (88.6%) 88 8 (9.1%) 80 (90.9%)
No 80 11 (13.8%) 69 (86.3%) 38 8 (21.1%) 30 (78.9%)
Tumour size (cm) 0.000 0.017
#5 59 15 (25.4%) 44 (74.6%) 76 14 (18.4%) 62 (81.6%)
>5 153 11 (7.2%) 142 (92.8%) 50 2 (4.0%) 48 (96%)
Tumour multiplicity 0.326 0.408
Single 128 18 (14.1%) 110 (85.9%) 87 12 (13.8%) 75 (86.2%)
Multiple 84 8 (9.5%) 76 (90.5%) 39 4 (10.3%) 35 (89.8%)
Differentiation 0.250 0.362
Well 24 6 (25.0%) 18 (75.0%) 16 4 (25%) 12 (75%)
Moderate 129 14 (10.9%) 115 (89.1%) 71 8 (11.3%) 63 (88.7%)
Poor 50 5 (10.0%) 45 (90.0%) 33 4 (12.1%) 29 (87.9%)
Undifferentiated 9 1 (11.1%) 8 (88.9%) 6 0 (0%) 6 (100%)
Stage 0.000 0.001
I 28 11 (39.3%) 17 (60.7%) 12 6 (50.0%) 6 (50.0%)
II 60 8 (13.3%) 52 (86.7%) 50 6 (12.0%) 44 (88.0%)
III 97 6 (6.2%) 91 (93.8%) 50 3 (6.0%) 47 (94.0%)
IV 27 1 (3.7%) 26 (96.3%) 14 1 (7.1%) 13 (92.9%)
Vascular invasion 0.075 0.023
Yes 108 9 (8.3%) 99 (91.7%) 57 3 (5.3%) 54 (94.7%)
No 104 17 (16.3%) 87 (83.7%) 69 13 (18.8%) 56 (81.2%)
Relapse 0.104 0.410
Yes 105 9 (8.6%) 96 (91.4%) 43 4 (9.3%) 39 (90.7%)
No 107 17 (15.9%) 90 (84.1%) 83 12 (14.5%) 71 (85.5%)
*c2 test.
yMean age.
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Statistical analysis
Statistical analyses were performed using the SPSS software
program (SPSS Standard version 13.0). Receiver operating char-
acteristic (ROC) curve analysis was applied to determine the
cut-point for marker positivity by the 0,1-criterion, and sensi-
tivity, specificity and the areas under the ROC curves (AUC)
were calculated. To combine the three markers (EZH2, HSP70
and GPC3), we found the linear coefficient to maximise AUC for
the combination. The associations between EZH2 expression
and other variables were analysed by using the Spearman rank
test. The statistical significance of the correlation between
biomarker expression and disease-specific survival was estimated
by the log-rank test. Multiple Cox proportional hazards regres-
sion was carried out to identify the independent factors which
had a significant impact on patient survival. A difference was
considered significant if the p value from a two-tailed test was
less than 0.05.
RESULTS
Protein expression levels of EZH2 in liver cell lines and tissues
by western blotting analysis
Western blotting analysis revealed an obviously higher level
of EZH2 expression in all six HCC cell lines than in normal
liver cell line Lo2, which was used for purposes of comparison
(figure 1A, left). In liver tissues, upregulated expression of EZH2
was noticed in all cases of primary HCC tissues, while the
level of expression of EZH2 was negligible in the adjacent
non-neoplastic liver tissues (figure 1A, right).
Figure 1 The expression of enhancer
of zeste homolog 2 (EZH2) in human
hepatocellular cells and tissues. (A) The
six hepatocellular carcinoma (HCC) cell
lines, Huh7, HepG2, 7402, 7721, Hep3B
and Lm3, exhibited higher levels of
EZH2 expression, as determined by
western blotting, than normal liver cell
line Lo2. Upregulated expression of
EZH2 was detected in all 10 cases of
primary HCC tissues compared to
adjacent non-neoplastic liver tissues. T,
hepatocellular carcinoma tissue; N,
non-neoplastic liver tissue. (B) Positive
expression of EZH2 was examined by
immunohistochemistry in HCC case No.
69. The adjacent non-neoplastic liver
tissues (case 69) and a dysplastic
nodule (DN) (case 9) negatively
expressed EZH2 (upper panels, H&E
staining; lower panels,
immunohistochemical staining; 3100).
(C) Left: the box plot shows the mean
staining intensity of EZH2 from HCC
and non-neoplastic liver in the testing
cohort (p<0.0001). Right: ROCs curves
of EZH2 (area under curve (AUC)¼
0.990, p<0.0001) in HCCs compared to
adjacent non-neoplastic liver tissues in
the testing cohort. (D) Left: the box
plots demonstrate the range of EZH2
expression within each group (HCC,
n¼126; DN, n¼37; non-neoplastic liver
tissues, n¼126) in the validation
cohort (p<0.0001). Right: ROC
curves comparing EZH2
(AUC¼0.935, p<0.0001),
HSP70 (AUC¼0.936, p<0.0001), GPC3
(AUC¼0.890, p<0.0001) and the
combination of the three markers
(AUC¼0.957, p<0.0001) in patients
with HCC versus adjacent non-
neoplastic liver tissues and DN. ROC,
receiver operating characteristics.
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Identification of expression pattern of EZH2 in HCC tissue by IHC
The degree of immunoreactivity of EZH2, which was observed
primarily in the hepatocellular cell nuclei, ranged from 0% to
100% (figure 1B). Semi-quantification of primary HCC (n¼212)
and adjacent non-neoplastic liver tissue (n¼212) in our testing
cohort demonstrated a mean EZH2 staining intensity of
65.94% (SE, 1.652%; 95% CI 62.69% to 69.20%) and 2.41% (SE,
0.492%; 95% CI 1.44% to 3.38%), respectively (Wilcoxon exact
test, p<0.0001, figure 1C, left). Overall, the sensitivity, specificity
and AUC values of EZH2 expression levels for HCC detection
versus non-neoplastic liver tissues were 95.8%, 97.8% and 0.990,
respectively (p<0.0001, figure 1C, right). These values indicate
that EZH2 is a potential diagnostic immunomarker for HCC.
Validation of EZH2 as an IHC diagnostic marker for HCC
To determine the reproducibility of these findings, the expres-
sion dynamics of EZH2 in HCC were next evaluated in our
validation cohort, which included 126 HCCs and 37 DNs, by
IHC. In this cohort, the mean staining intensity of EZH2 in
HCCs was 63.73% (SE, 2.259%; 95% CI 59.26% to 68.20%),
which was significantly higher than those in the adjacent non-
neoplastic liver tissues (mean, 4.01%; SE, 0.647%; 95% CI 2.73%
to 5.29%) and in DNs (mean, 17.16%; SE, 3.139%; 95% CI
10.80% to 23.53%; Wilcoxon exact test, p<0.0001, figure 1D,
left). Further analysis also showed a significant difference in the
expression percentages of EZH2 between the WD HCCs (mean,
60.81%) and the DNs (mean, 17.16%, Wilcoxon exact test,
p<0.0001). Overall, the sensitivity, specificity and AUC for the
diagnosis of HCC versus DN/non-neoplastic liver tissue using
the expression levels of EZH2 above were 83.3%, 90.9% and
0.935, respectively (p<0.0001, figure 1D, right).
Since HSP70 and GPC3 have recently been suggested as
promising biomarkers for distinguishing between malignant and
non-malignant hepatocellular lesions,17 20 we also compared the
diagnostic performance of EZH2 for HCC with that of HSP70
and GPC3. We further investigated whether a combination of
these three potential markers improved their ability to diagnose
HCC. The results demonstrated that HSP70 and GPC3 immu-
noreactivity were primarily examined in the nucleocytoplasm
and cytoplasm, respectively (figure 2A). The sensitivity, speci-
ficity and AUC values for HCC diagnosis were 82.8%, 92.7% and
0.936 when HSP70 was used, and 77.0%, 90.4% and 0.890 when
GPC3 was used (p<0.0001, figure 1D, right). Strikingly, the
sensitivity, specificity and AUC values increased to 89.7%, 94.5%
and 0.957, when EZH2 was combined with HSP70 and GPC3
(p<0.0001, figure 1D, right). Furthermore, for the detection of
WDHCCs, the sensitivity and specificity of individual markers or
a combination were 68.9% and 91.5% for EZH2, 62.5% and 98.5%
for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for
the three-marker panel (ie, a combination of EZH2, HSP70 and
GPC3). A comparison for ROC curves showed that the AUC for
the three-marker combination (EZH2, HSP70 and GPC3) was
significantly larger than that for GPC3 alone (p¼0.010), while
there were no significant differences of AUC between the three-
marker combination and EZH2 or HSP70 alone and between each
of the three markers (p>0.05). These findings indicate (a) that
EZH2 alone is more sensitive for the diagnosis of WD HCC than
either HPS70 or GPC3, and (b) that the combination of the three
markers could greatly improve the diagnostic accuracy of HCC,
particularly for WD HCC detection (figure 2B).
Potential diagnostic utility of EZH2, HSP70 and GPC3 for HCC
detection in liver needle biopsies
In clinical settings, a needle biopsy is normally recommended to
identify the features of malignancy when small hepatic nodules
are detected. Additional biomarkers for the discrimination of
WD HCC and DN are needed.27 To evaluate the diagnostic
values of EZH2 and the three-marker combination (EZH2,
Figure 2 The expression dynamics of enhancer of zeste homolog 2 (EZH2), heat shock protein 70 (HSP70) and glypican 3 (GPC3) examined by
immunohistochemistry in hepatocellular carcinoma (HCC) resection tissues. (A) A moderately differentiated HCC case positively expresses EZH2,
HSP70 and GPC3. (B) A well-differentiated HCC case positively expresses EZH2 and HSP70, but negatively expresses GPC3.
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HSP70 and GPC3) in liver needle biopsy samples, we further
performed IHC examinations of EZH2, HSP70 and GPC3 in an
additional cohort of 129 biopsy specimens with hepatic nodules.
To identify a single, optimal cut-point for positivity, ROC curve
analysis was applied to the cohort of surgical resection tissues to
determine the cut-off score for positive expressions of the three
markers concerned. The score closest to the point with both
maximum sensitivity and specificity, that is, the point (0.0, 1.0)
on the curve, was selected as the cut-off score, leading to the
greatest number of patients correctly classified as HCC or non-
Figure 3 The expression patterns enhancer of zeste homolog 2 (EZH2), heat shock protein 70 (HSP70) and glypican 3 (GPC3) examined by
immunohistochemistry in liver needle biopsy tissues. (A) A poorly differentiated hepatocellular carcinoma (HCC) biopsy tissue positively expresses EZH2,
HSP70 and GPC3, while the adjacent non-neoplastic liver tissues show negative staining of the three markers. (B) A moderately differentiated HCC biopsy
case shows positive immunostaining of EZH2 and GPC3, but only weak immunostaining by HSP70. (C) A dysplastic nodule biopsy case negatively
expresses EZH2, HSP70 and GPC3. Representative sites in liver needle biopsy tissue at low (3100) and high (inset, 3400) magnification are shown.
Table 2 Immunohistochemical analysis of the different lesions in liver needle biopsies
LRN HA FNH DN WD HCC MD HCC PD HCC
n[6 n[6 n[20 n[25 n[18 n[37 n[17
All three positive 0 0 0 0 4 16 6
At least two positive 0 0 0 0 11 32 15
At least one positive 0 0 2 7 16 37 17
EZH2+/HSP70+ 0 0 0 0 7 22 8
EZH2+/GPC3+ 0 0 0 0 6 21 10
HSP70+/GPC3+ 0 0 0 0 6 21 9
EZH2+ 0 0 1 3 12 31 13
HSP70+ 0 0 1 2 10 28 11
GPC3+ 0 0 0 2 9 26 14
DN, dysplastic nodule; FNH, focal nodular hyperplasia; HA, hepatocellular adenoma; LRN, large regenerative nodule; MD HCC,
moderately differentiated hepatocellular carcinoma; PD HCC, poorly differentiated hepatocellular carcinoma; WD HCC, well-
differentiated hepatocellular carcinoma.
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HCC. Thus, tumours designated positive for EZH2, HSP70 and
GPC3 were those with scores above the value of 30%, 10% and
10%, respectively. By using these criteria, in our biopsy tissues, all
12 cases of LRN/HAwere negatively stained by each of the three
markers, whereas the number of immuno-positive cases for
which there was at least one marker increased from 2/20 (10.0%)
in the case of FNHs to 7/25 (28.0%) for DNs and to 16/18 (88.9%)
for WD HCCs; and to 54/54 (100.0% in the case of moderately
differentiated (MD) + poorly differentiated (PD) HCCs (figure
3A,B, table 2). Immuno-positive cases for which there were at
least two markers (regardless of their identity) were observed in
0/6 LRNs, in 0/6 HAs, in 0/20 FNHs, in 0/25 DNs (figure 3C), in
11/18 (61.1%)WDHCCs, in 32/37 (86.5%)MDHCCs, and in 15/
17 (88.2%) PDHCCs (table 2). Further statistical analysis showed
that when at least one positive marker was considered, the
sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), accuracy and Youden index for differen-
tiating HCCs from non-malignant nodules were 97.2%, 84.2%,
88.6%, 96.0%, 91.5% and 0.81, respectively. When at least two
positive markers were used, the sensitivity, specificity, PPV, NPV,
accuracy and Youden index were 80.6%, 100%, 100%, 80.3%,
89.2% and 0.81%, respectively (table 3).
Association between EZH2 expression and clinico-pathological
features and survival of patients with HCC
Using the ROC curve of EZH2 described before, the positive
expression of EZH2 was examined in 186/212 (87.7%) of HCCs
in the testing cohort and in 110/126 (87.3%) of HCCs in the
validation cohort, respectively. Further correlation analysis in
both cohorts showed that the positive expression of EZH2 in
HCCs was significantly associated with a more aggressive
phenotype of the tumour (p<0.05, table 1). KaplaneMeier
analysis established that, in the testing cohort, the
median disease-specific survival time for patients with HCCwho
positively expressed EZH2 was 34.8 months, compared to
66.5 months for patients with HCC who negatively expressed
EZH2 (p¼0.001, log-rank test, figure 4A, table 4). In the valida-
tion cohort, patients with HCC who positively expressed EZH2
also exhibited a shorter survival time (median survival time,
33.5 months) than patients with HCC who negatively expressed
EZH2 (median, 49.2 months; p¼0.009, log-rank test, figure 4B,
table 4). Further multivariate Cox regression analysis indicated
that EZH2 expression is an independent prognostic factor for
poor survival of HCC patients in both cohorts (table 5).
DISSCUSSION
The polycomb group protein EZH2 has recently been suggested to
play a crucial role in the tumourigenesis of several types of human
cancer, including HCC.10e12 We previously found that the
knocking down of EZH2 by shRNA can significantly inhibit the
growth of HCC cells in vitro and their tumourigenicity in vivo.13
Several reports noted that EZH2was over-expressed inmost of the
HCCresection tissues by IHC,whereas itwasnegatively expressed
in nearly all the corresponding non-tumour tissues and DNs.14 16
These observations indicate that it may be possible to use the
expression levels of EZH2 as a diagnostic tool to distinguish HCC
tissues from non-malignant liver tissues. To date, however, studies
of the use of EZH2 in HCC cases have defined EZH2 protein
expression using a predetermined and arbitrary cut-off score.
Furthermore, no investigation and validation studies are available.
In the present study, our initial western blotting established
that EZH2 was expressed at a higher level in a panel of HCC cell
lines and tissues than in a hepatic cell line and adjacent liver
tissues. We next used IHC staining to examine the expression
dynamics of EZH2 in two large independent (testing and vali-
dation) cohorts of HCCs and non-malignant liver tissues.
According to our results, the mean staining intensity of EZH2 in
HCCs in both cohorts was significantly greater than in non-
Table 3 Degree of diagnostic accuracy in HCC and non-malignant (NM) nodules (whole series)
HCC
(n[72)
NM
(n[57) Sensitivity Specificity PPV NPV Accuracy
Youden
index
All three positive 26 0 36.1% 100% 100% 55.3% 64.3% 0.36
At least two positive 58 0 80.6% 100% 100% 80.3% 89.2% 0.81
At least one positive 70 9 97.2% 84.2% 88.6% 96.0% 91.5% 0.81
EZH2+/HSP70+ 37 0 51.4% 100% 100% 62.0% 72.9% 0.51
EZH2+/GPC3+ 37 0 51.4% 100% 100% 62.0% 72.9% 0.51
HSP70+/GPC3+ 36 0 50.0% 100% 100% 61.3% 72.1% 0.50
EZH2+ 56 4 77.8% 93.0% 93.3% 76.8% 84.5% 0.71
HSP70+ 49 3 68.1% 94.7% 94.2% 70.1% 79.8% 0.63
GPC3+ 49 2 68.1% 96.5% 94.2% 70.5% 80.6% 0.65
NPV, negative predictive value; PPV, positive predictive value.
Figure 4 KaplaneMeier survival
analysis according to enhancer of zeste
homolog 2 (EZH2) protein expression in
338 patients with hepatocellular
carcinoma (log-rank test). (A)
Probability of survival of patients in
testing cohort: negative expression of
EZH2, n¼26; positive expression of
EZH2, n¼186 (p¼0.001). (B)
Probability of survival of patients in
validation cohort: negative expression
of EZH2, n¼16; positive expression of
EZH2, n¼110 (p¼0.009).
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malignant liver tissues. The expression levels of EZH2 were able
to distinguish HCCs from non-malignant liver tissues with very
high sensitivity, specificity and AUC. Furthermore, the staining
intensity of EZH2 in WD HCCs was significantly greater than
that in DNs. These observations strongly suggest that the
evaluation of EZH2 expression by IHC can enable us not only to
discriminate HCCs and non-neoplastic liver tissues, but also to
distinguish WD HCCs from DNs with a high degree of accuracy.
In clinical practice, an increasing number of small hepatocel-
lular nodules (<3 cm) are detected by imaging during the follow-
up of patients with liver cirrhosis, but the sensitivity of this
imaging for the detection of small HCCs is only around 33%.28 29
Recently, liver needle biopsies have been recommended as
a check on diagnoses of small hepatic nodules which were not
satisfactorily addressed by imaging. However, since histological
diagnosis by needle liver biopsy is based solely on the analysis of
tiny fragments of the tissue, it is very difficult to distinguish
between early WD HCCs and certain benign hepatocellular
diseases such as DNs. This often results in diagnostic
delays.30e33 A number of biomarkers have been suggested that
can potentially distinguish HCCs from DNs in cirrhosis cases.
The diagnostic yield of a panel of putative HCC markers, such as
HSP70, GPC3 and glutamine synthetase has been examined,
and they have been proposed as useful immunomarkers for
HCC.21 22 In this study, the diagnostic performance of HSP70 or
GPC3 and their combination with EZH2 was first analysed in
our surgical resection liver specimens. As expected, both HSP70
and GPC3 alone showed a high sensitivity, specificity and AUC
for HCC detection. Interestingly, the sensitivity, specificity and
AUC for HCC diagnosis increased when EZH2 was used in
combination with HSP70 and GPC3. In addition, for the diag-
nosis of WD HCCs, the sensitivity and specificity of individual
markers or a combination were 68.9% and 91.5% for EZH2,
62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and
75.0% and 100% for the 3-marker panel.
We wondered whether the expression status of EZH2would be
retained in liver needle biopsies, thereby also serving as a useful
diagnostic immunomarker to distinguish between HCCs and
benign hepatocellular tissues. We therefore re-evaluated the diag-
nostic values of EZH2 and the three-marker combination (EZH2,
HSP70 and GPC3) in an additional cohort of liver needle biopsy
samples. By using the cut-off score established in ROC curve
analysis before,we found that in liver biopsies, LRNs andHAswere
all stained negatively by each of the three markers, whereas
Table 4 Univariate analysis of enhancer of zeste homolog 2 (EZH2) expression and various
clinicopathological parameters in 338 patients with primary hepatocellular carcinoma
Variable
Testing cohort Validation cohort
All cases HR (95% CI) p value* All cases HR (95% CI) p Value*
Age (years) 0.627 0.721
#47.9y 105 1.0 61 1.0
>47.9 107 1.090 (0.770 to 1.542) 65 1.109 (0.628 to 1.959)
Sex 0.045 0.558
Male 174 1.650 (1.012 to 2.688) 109 1.293 (0.548 to 3.052)
Female 38 1.0 17 1.0
Hepatitis history 0.810 0.991
Yes 164 1.053 (0.692 to 1.602) 107 1.004 (0.450 to 2.240)
No 48 1.0 19 1.0
AFP (ng/ml) 0.000 0.000
#20 67 1.0 56 1.0
>20 145 2.262 (1.490 to 3.434) 70 5.305 (2.826 to 9.958)
Liver cirrhosis 0.891 0.983
Yes 132 0.975 (0.682 to 1.395) 88 1.0
No 80 1.0 38 0.993 (0.539 to 1.831)
Tumour size (cm) 0.000 0.000
#5 59 1.0 76 1.0
>5 153 6.295 (3.688 to 10.747) 50 2.839 (1.586 to 5.082)
Tumour multiplicity 0.000 0.000
Single 128 1.0 87 1.0
Multiple 84 3.480 (2.429 to 4.987) 39 3.672 (2.065 to 6.529)
Differentiation 0.021 0.102
Well-moderate 153 1.0 87 1.0
Poor-undifferentiated 59 1.534 (1.068 to 2.203) 39 1.630 (0.908 to 2.927)
Stage 0.000 0.000
IeII 88 1.0 62 1.0
IIIeIV 124 5.393 (3.525 to 8.252) 64 5.400 (2.526 to 11.542)
Vascular invasion 0.000 0.000
Yes 108 4.923 (3.310 to 7.322) 57 5.362 (2.724 to 10.553)
No 104 1.0 69 1.0
Relapse 0.000 0.000
Yes 105 1.907 (1.330 to 2.734) 43 2.860 (1.600 to 5.112)
No 107 1.0 83 1.0
EZH2 0.001 0.009
Negative expression 26 1.0 16 1.0
Positive expression 186 3.506 (1.703 to 7.219) 110 5.451 (1.318 to 22.543)
*c2 test.
yMean age.
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immuno-positive cases for at least onemarker increased from FNH
(2/20) and DN (7/25) to WDHCC (16/18), and to MD+PD HCC
(54/54). Using the three-marker panel, immuno-positive cases
(ie, caseswhere any twomarkers showedpositive)were observed in
none of the benign liver lesions, but were frequently examined in
11/18 WD HCCs, in 32/37 MD HCCs, and in 15/17 PD HCCs.
Further statistical analysis determined that sensitivity was 97.2%
when at least one marker was used, but only 80.6% when at least
two markers were used. Specificity increased from 84.2% when at
least onemarkerwas used, to 100%whenat least twomarkerswere
used; while the PPV increased from 88.6% to 100%. The accuracy
and Youden index remained nearly or exactly identical. These
findings were intriguing, since PPV is highly useful in both marker
situations as well as for NPV. Collectively, our findings not only
confirm the value of EZH2 for the detection of HCC, but also
demonstrate that the use of a three-marker panel (EZH2, HSP70
and GPC3) can improve the rate of detection of HCCs in liver
biopsy tissues.
To sum up, in this study we describe the protein expression
patterns of EZH2 in several cohorts of human HCCs and non-
malignant liver tissues, and demonstrate the potential utility of
EZH2 as an immunomarker of HCCs during the diagnosis of liver
lesions. We show, for the first time, that a three-marker panel (ie,
EZH2, HSP70 and GPC3) is better able to identify HCCs in liver
biopsy tissues than EZH2 alone. Our results also provide evidence
that the positive expression of EZH2 in HCCs may be important
for the detection of an aggressive phenotype or a phenotype with
poor prognosis. We believe that the use of EZH2 protein, as
examined by IHC, as a diagnostic biomarker of HCCs could
improve the prospects of the early detection ofHCCs in liver needle
biopsies; and that an improved rate of detection would have
important prognostic implications for patients with HCC. It is
necessary to point out that our current study is of the retrospective
nature. Themain limitations of this study are that (a) patientswith
lesions confidently classified asHCCbybiopsy and explant analysis
were included; and (b) a high proportion of large lesions (>5 cm)
was included in our surgically resected HCC cohorts to establish
the diagnostic criteria of biomarkers, in which the diagnosis by
haematoxylin&eosin is usually not difficult. Clearly, further
prospective studies designed to include HCC lesions smaller than
2 cm are needed to validate the conclusions of this study.
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Editor’s quiz: GI snapshot
ANSWER
From the question on page 922
The diagnosis was acute pancreatitis complicated with
pseudo-cyst and pseudo-aneurysm of splenic artery.
The colour Doppler and three-dimensional sonogram revealed
the nodule to be hyper-vascular and communicating with the
splenic artery (figures 1 and 2). A CT scan (figure 3) and its
volume rendering reformatted angiography (figure 4) showed
a pseudo-cyst and a pseudo-aneurysm from the splenic artery.
Therefore, acute pancreatitis complicated with a pseudo-cyst
and pseudo-aneurysm was diagnosed. The pseudo-aneurysm
was removed by surgery uneventfully and minimal rupture was
disclosed during the operation.
Rupture of a pseudo-aneurysm is a rare complication of
pancreatitis, and is associated with poor prognosis. The
mortality correlates with the severity of the pseudo-aneurysm
and the overall mortality of acute pancreatitis, around 7.8%. The
pseudo-aneurysm caused by acute pancreatitis usually develops
at superior mesentery artery, splenic artery or gastro-duodenal
artery with manifestation of gastro-intestine bleeding, haemo-
bilia, obstructive jaundice, or internal bleeding. Angiography is
usually required for confirmation of the diagnosis. Non-invasive
imaging techniques such as colour Doppler ultrasound and
contrast-enhanced CT scan are also useful in diagnosing pancre-
atic pseudo-aneurysm associated with acute pancreatitis.1e3
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Figure 1 Three-dimensional sonogram.
Figure 2 Color Doppler sonogram.
Figure 3 Pseudo-aneurysm from the splenic artery by CT scan.
Figure 4 Reformatted angiography. The arrow indicates the pseudo-
aneurysm.
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